Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
The systemic lupus erythematosus (SLE) market will experience dramatic growth, increasing from approximately $300 million in 2010 to $2.8 billion in 2020 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan... Learn More
Recorded live on May 2, 2012 ...Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Snapshot: AAN 2012 Physician Insight on Recent Developments in Multiple Sclerosis and New Data Presented at the 64th Annual Meeting of the American Academy of Neurology
Decision Resources finds that 90 percent of U.S. neurologists surveyed report a willingness to prescribe Biogen Idec’s BG-12 for the treatment of multiple sclerosis following the release of detailed results from the CONFIRM Phase III clinical trial, which were showcased at the 64th annual meeting of the American Academy of Neurology (AAN) in April 2012.
May 15, 2012
For the Treatment of Osteoarthritic Pain, Clinical Data and Interviewed Thought Leaders Indicate That Tanezumab Has Advantages Over Celebrex
May 14, 2012
Following the Release of Detailed Results From the Confirm Study at the 64th Annual Meeting of the American Academy of Neurology, 90 Percent of Surveyed U.S. Neurologists Report Willingness to Prescribe Biogen Idec’s BG-12
May 9, 2012
Surveyed U.S. Gastroenterologists and MCO Pharmacy Directors Say Improvement in Overall Symptoms of IBS Remains a Significant Unmet Need; Asimadoline, MuDelta and LX-1033 Have Demonstrated the Potential to Partially Fulfill This Unmet Need
Irritable Bowel Syndrome: Decision Resources' Market Forecast and Opportunity Analysis
Irritable Bowel Syndrome: Decision Resources' Market Forecast and Opportunity Analysis is an Executive Summary... Read More
Alzheimer's Disease (Event Driven)
Last Updated 15 May 2012The Alzheimer’s disease (AD) patient population is large and growing rapidly as the... Read More
Rheumatoid Arthritis: Rheumatologists Will Accept Trade-Offs in Safety for an Oral Agent That Is as Efficacious as Humira and Priced at a Significant Discount
Over the last several years, the rheumatoid arthritis (RA) therapy market has become saturated with biologics. Although... Read More